TRPM4-specific blocking antibody attenuates reperfusion injury in a rat model of stroke
Authors:
Open Access
- 29 October 2019
- journal article
- research article
- Published by Springer Nature in Pflügers Archiv - European Journal of Physiology
- Vol. 471 (11-12) , 1455-1466
Abstract
Reperfusion therapy is currently the gold standard treatment for acute ischemic stroke. However, reperfusion injuries such as oedema and haemorrhagic transformation largely limit the use of this potent treatment to a narrow time window. Recently, transient receptor potential melastatin 4 (TRPM4) channel has emerged as a potential target for vascular protection in stroke management. Non-specificity and side effects are major concerns for current TRPM4 blockers. The present study was undertaken to develop a novel TRPM4 blocker for stroke management. We report the generation of a TRPM4-specific antibody M4P which binds to a region close to the channel pore. M4P could inhibit TRPM4 current and downregulate TRPM4 surface expression, therefore prevent hypoxia-induced cell swelling. In the rat model of 3-h stroke reperfusion, application of M4P at 2 h after occlusion ameliorated reperfusion injury by improving blood–brain barrier integrity, and enhanced functional recovery. Our results demonstrate that TRPM4 blockade could attenuate reperfusion injury in stroke recanalization. When applied together with reperfusion treatments, TRPM4 blocking antibody has the potential to extend the therapeutic time window for acute ischemic stroke.Keywords
Funding Information
- Singapore Ministry of Health’s National Medical Research Council (NMRC/OFIRG/0070/2018, NMRC/CIRG/1425/2015)
This publication has 37 references indexed in Scilit:
- Oncotic Cell Death in Stroke2018
- Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trialThe Lancet Neurology, 2016
- Glyburide is Associated with Attenuated Vasogenic Edema in Stroke PatientsNeurocritical Care, 2013
- The DPP-4 Inhibitor Linagliptin Counteracts Stroke in the Normal and Diabetic Mouse BrainDiabetes, 2013
- The Sulfonylurea Receptor 1 (Sur1)-Transient Receptor Potential Melastatin 4 (Trpm4) ChannelJournal of Biological Chemistry, 2013
- Sulfonylurea Use Before Stroke Does Not Influence OutcomeStroke, 2011
- De novo expression of Trpm4 initiates secondary hemorrhage in spinal cord injuryNature Medicine, 2009
- Insights into TRPM4 Function, Regulation and Physiological Role2007
- KATP channels as molecular sensors of cellular metabolismNature, 2006
- Sulfonylurea Drugs Do Not Influence Initial Stroke Severity and In-Hospital Outcome in Stroke Patients With DiabetesStroke, 2001